Catalent stockholders approve transaction with Novo Holdings

Catalen announced that, at its Special Meeting of Stockholders held earlier, its stockholders voted to approve the pending transaction under which Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash . “Today’s outcome represents an important milestone towards the closing of this transaction, and we thank our stockholders for their overwhelming support and their confidence in the future of Catalent,” said Alessandro Maselli, President and Chief Executive Officer of Catalent. “Following the closing of the transaction, we look forward to writing the next chapter for Catalent, benefiting from Novo Holdings’ expertise and resources as we continue to be a global leading independent CDMO, developing, manufacturing and supplying products that help people live better and healthier lives.” Based on the preliminary count of the voting results from today’s Special Meeting, Catalent stockholders voted to approve the transaction with 99.2% of ballots cast in favor of the proposed transaction. Catalent anticipates filing the final voting results for its Special Meeting in a Form 8-K with the Securities and Exchange Commission, after certification by Catalent’s inspector of elections. The transaction is expected to close towards the end of calendar year 2024, subject to customary closing conditions, including receipt of required regulatory approvals. The transaction is not subject to any financing contingency.